Incomplete biomarker testing can lead to inappropriate treatment selection
Fewer than 20% of advanced NSCLC patients get complete guideline-recommended biomarker testing9
The number of biomarkers guidelines recommend testing advanced NSCLC patients for before treatment
The list of biomarkers that are matched with an FDA-approved targeted therapy is growing.
2 in 3 NSCLC patients
have a biomarker that can be targeted with available therapies10
Matching advanced NSCLC patients to targeted therapy using biomarker testing results improves outcomes11
Sotorasib (LUMAKRAS™)18 significantly
increases PFS compared to docetaxel11
Sotorasib targets KRAS G12C, one of the most common NSCLC biomarkers. 1 in 8 patients with advanced lung cancer has a KRAS G12C mutation.10
Advanced NSCLC patients with targetable mutations should not be treated with immunotherapy1
of NSCLC patients could get the wrong treatment because their doctors fail to order complete biomarker testing.9
One chance to make the right decision
There may be just one opportunity for a doctor to make the right decision about a patient’s first-line treatment for advanced NSCLC.